Singapore markets closed

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.8800+0.1600 (+9.30%)
At close: 04:00PM EDT
1.9200 +0.04 (+2.13%)
Pre-market: 08:17AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 479.29M
Enterprise value 8.14M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.97k
Price/book (mrq)0.79
Enterprise value/revenue 119.78
Enterprise value/EBITDA 0.25

Trading information

Stock price history

Beta (5Y monthly) -0.53
52-week change 3-43.88%
S&P500 52-week change 324.13%
52-week high 33.4100
52-week low 31.1800
50-day moving average 32.2413
200-day moving average 32.0742

Share statistics

Avg vol (3-month) 31.01M
Avg vol (10-day) 3767.35k
Shares outstanding 5254.94M
Implied shares outstanding 6254.94M
Float 8164.22M
% held by insiders 115.40%
% held by institutions 167.24%
Shares short (28 Jun 2024) 417.92M
Short ratio (28 Jun 2024) 412.51
Short % of float (28 Jun 2024) 49.99%
Short % of shares outstanding (28 Jun 2024) 47.03%
Shares short (prior month 31 May 2024) 420.2M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,852,500.00%

Management effectiveness

Return on assets (ttm)-18.93%
Return on equity (ttm)-32.93%

Income statement

Revenue (ttm)68k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-95.40%
Gross profit (ttm)N/A
EBITDA -218.27M
Net income avi to common (ttm)-228.34M
Diluted EPS (ttm)-0.9000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)526.3M
Total cash per share (mrq)2.06
Total debt (mrq)61.83M
Total debt/equity (mrq)10.25%
Current ratio (mrq)16.51
Book value per share (mrq)2.37

Cash flow statement

Operating cash flow (ttm)-159.5M
Levered free cash flow (ttm)-84.19M